← Back to Search

Cannabinoid

Full-Spectrum Hemp-Derived CBD (fsCBD) for Pain (QUARTz Trial)

Phase 2

Waitlist Available

Research Sponsored by University of Colorado, Boulder

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4 weeks, 8 weeks

Awards & highlights

QUARTz Trial Summary

This trial aims to study the effects of cannabis on older adults who use it for pain, anxiety, or mood issues. Participants will be randomly assigned to receive hemp-derived CBD+THC, hemp-derived

Who is the study for?

This trial is for older adults who use cannabis to manage pain, anxiety, or mood problems like depression. Participants will be randomly assigned to one of three groups: one receiving hemp-derived CBD with THC (fsCBD), another getting CBD without THC (bsCBD), and a placebo group.Check my eligibility

What is being tested?

The study aims to test the effectiveness of two types of cannabidiol (CBD) as a harm reduction strategy for older cannabis users over an 8-week period. It compares full-spectrum CBD that includes THC (fsCBD) and broad-spectrum CBD that excludes THC (bsCBD) against a placebo.See study design

What are the potential side effects?

Potential side effects may include changes in appetite, mood alterations, dizziness, dry mouth, or fatigue. These are common when using products containing cannabinoids such as CBD and THC.

QUARTz Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4 weeks, 8 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4 weeks, 8 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks, 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Anxiety

Balance

Blood Cytokine Levels

+13 more

Secondary outcome measures

Polypharmacy-Pain Medications

Polypharmacy-Psychiatric Medications

Polypharmacy-Sleep Medications

+2 more

QUARTz Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: Full-Spectrum Hemp-Derived CBD (fsCBD)Experimental Treatment1 Intervention

8 weeks of use of a daily dose of cannabis (200mg CBD/4mg THC)

Group II: Broad-Spectrum Hemp-Derived CBD (bsCBD)Experimental Treatment1 Intervention

8 weeks of use of a daily dose of cannabis (200mg CBD)

Group III: PlaceboPlacebo Group1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Colorado, BoulderLead Sponsor

119 Previous Clinical Trials

28,809 Total Patients Enrolled

2 Trials studying Pain

236 Patients Enrolled for Pain

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the safety profile of Full-Spectrum Hemp-Derived CBD (fsCBD) in individuals?

"Based on our assessment at Power, the safety rating for Full-Spectrum Hemp-Derived CBD (fsCBD) is a 2 on a scale of 1 to 3. This evaluation corresponds to Phase 2 trials where some safety data exists but efficacy data is lacking."

Answered by AI

What are the specific goals and objectives of this research study?

"The primary focus of this investigation, to be assessed at Baseline, 4 weeks, and 8 weeks post-treatment initiation, is the impact of the drug. Additional goals consist of monitoring Polypharmacy-Psychiatric Medications (referring to psychiatric medication usage), Polypharmacy-Sleep Medications (pertaining to sleep aid consumption), and assessing Strength and Endurance through a 30-second chair stand task measuring leg strength by how many times participants can rise from a chair within that time frame."

Answered by AI

Are individuals currently eligible to apply for participation in this ongoing medical study?

"Information on clinicaltrials.gov shows that this particular trial is not currently seeking participants. The trial was first listed on March 1, 2024, with the most recent update made on February 25, 2024. Despite its current inactivity regarding patient enrollment, there are approximately 1984 alternative clinical trials actively searching for suitable candidates at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Cannabidiol and Older Adult Cannabis Users

Angela Bryan 2024. "Cannabidiol and Older Adult Cannabis Users". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06290063.

All > Cbd > Epidiolex